New Pharma Benchmark Report to Address Lack of Strategic Intelligence Solutions

Friday 27 July 2012, Amsterdam

As emerging economies and medical advances continue to broaden the healthcare landscape, pharmaceutical market observers are finding there’s a lack of strategic intelligence that accounts for an increasingly diverse industry — a problem that the new Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers report hopes to provide a solution for.

The 2012 Pharmaceutical Benchmark Report addresses the current inadequacies in pharmaceutical analysis by providing in-depth analysis on the top 25 pharmaceutical companies from 2011 by therapy area and region, offering a new and actionable perspective on what has become an outdated understanding of what makes a successful business model.

Analyst for healthcare industry dynamics and author of the report, Adam Dion, MS, said: “There is no one-size-fits-all strategy for success in the pharmaceutical industry. Rather, each successful company uses its own mixture of business approaches to attempt to optimize achievement in particular therapeutic or geographic areas”.

“Focusing on top-line revenues or market share gives an incomplete picture of successful pharmaceutical enterprises. By looking at margins, growth and penetration into new markets, we can gain a more comprehensive understanding of the most successful companies.”

A proprietary ranking system revealed that the top performing pharmaceutical company in 2011 was Merck & Co., with other leading performances from companies such as Novartis, Celgene, Teva Pharmaceuticals, Roche and Novo Nordisk.

The report provides comprehensive analysis on the key issues affecting the industry, such as the need to find innovate strategies to compensate from losses stemming from the patent cliff and the rise of the BRIC nations, and how leading companies have adapted and excelled.

Key drivers and trends across all traditional and developing economies are explored, along with detailed assessments of the leading drug manufacturers in the six major therapeutic areas of cardiovascular diseases, central nervous system (CNS), diabetes and metabolics, immunology, oncology, and respiratory diseases.

This report integrates deep research of top players in the pharmaceutical industry with our proprietary analysis and ranking methodology to reveal top performers, industry trends, and the strategies that successful companies are using to stay ahead in the increasingly demanding pharmaceutical marketplace.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.